Literature DB >> 12495641

Strategies for chemokine antagonists as therapeutics.

Amanda E I Proudfoot1, Christine A Power, Christian Rommel, Timothy N C Wells.   

Abstract

Chemokines are responsible for specific recruitment of leukocytes that are involved both in homing as well as in inflammation. Dysregulation of the system results in excessive recruitment to inflammatory sites and thus prevention of this recruitment is an effective anti-inflammatory strategy. Chemokine receptors are not limited only to cellular recruitment but are also the essential co-factor along with CD4 that enable HIV-1 viruses to infect cells. In this review we discuss the various points of intervention that can be addressed to provide anti-inflammatory and anti-HIV infectivity therapeutics. These include prevention of the receptor-ligand interaction, prevention of the chemokine-glycosaminoglycan interaction, interfering with the signaling pathways that are induced upon receptor activation, and modification of receptor trafficking pathways. We summarize the status of the approaches that have been undertaken to produce therapeutics that block chemokine action.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12495641     DOI: 10.1016/s1044-5323(02)00128-8

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  19 in total

Review 1.  Chemokine receptors and leukocyte trafficking in the mucosal immune system.

Authors:  Ifor R Williams
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 2.  Chemokines and glial cells: a complex network in the central nervous system.

Authors:  Elena Ambrosini; Francesca Aloisi
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

3.  The green tea polyphenol (-)-epigallocatechin-3-gallate inhibits leukocyte activation by bacterial formylpeptide through the receptor FPR.

Authors:  Jingjing Zhu; Oumei Wang; Lingfei Ruan; Xinwei Hou; Youhong Cui; Ji Ming Wang; Yingying Le
Journal:  Int Immunopharmacol       Date:  2009-05-06       Impact factor: 4.932

4.  Fractalkine receptor polymorphism may not be associated with the development and clinical course of ulcerative colitis.

Authors:  Hale Gokcan; Erkan Yurtcu; Haldun Selcuk; Feride I Sahin
Journal:  Bosn J Basic Med Sci       Date:  2015-05-25       Impact factor: 3.363

5.  Treatment of ovalbumin-induced experimental allergic bronchitis in rats by inhaled inhibitor of secretory phospholipase A(2).

Authors:  D Shoseyov; H Bibi; S Offer; O Schwob; M Krimsky; M Kleiman; S Yedgar
Journal:  Thorax       Date:  2005-06-30       Impact factor: 9.139

6.  Enhanced recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease.

Authors:  Miquel Sans; Silvio Danese; Carol de la Motte; Heitor S P de Souza; Brenda M Rivera-Reyes; Gail A West; Manijeh Phillips; Jeffry A Katz; Claudio Fiocchi
Journal:  Gastroenterology       Date:  2006-10-12       Impact factor: 22.682

7.  Therapeutic targeting of CCR1 attenuates established chronic fungal asthma in mice.

Authors:  Kristin J Carpenter; Jillian L Ewing; Jane M Schuh; Traci L Ness; Steven L Kunkel; Monica Aparici; Montserrat Miralpeix; Cory M Hogaboam
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

8.  Potential inhibitors of chemokine function: analysis of noncovalent complexes of CC chemokine and small polyanionic molecules by ESI FT-ICR mass spectrometry.

Authors:  Yonghao Yu; Matthew D Sweeney; Ola M Saad; Julie A Leary
Journal:  J Am Soc Mass Spectrom       Date:  2006-02-28       Impact factor: 3.109

9.  The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL 12) is altered by pH, phosphate, sulfate, and heparin.

Authors:  Christopher T Veldkamp; Francis C Peterson; Adam J Pelzek; Brian F Volkman
Journal:  Protein Sci       Date:  2005-03-01       Impact factor: 6.725

10.  Primed Mycobacterial Uveitis (PMU): Histologic and Cytokine Characterization of a Model of Uveitis in Rats.

Authors:  Kathryn L Pepple; Lauren Rotkis; Jennifer Van Grol; Leslie Wilson; Angela Sandt; Deborah L Lam; Eric Carlson; Russell N Van Gelder
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.